![]() |
市場調査レポート
商品コード
920154
主要抗がん剤10種の世界市場:地域別(欧州・アジア太平洋地域・ラテンアメリカ・中東・アフリカ) - 機会分析、および産業予測(2018年~2026年)Top 10 Cancer Drugs Market by Region (Europe, Asia-Pacific, and LAMEA): Opportunity Analysis and Industry Forecast, 2018-2026 |
主要抗がん剤10種の世界市場:地域別(欧州・アジア太平洋地域・ラテンアメリカ・中東・アフリカ) - 機会分析、および産業予測(2018年~2026年) |
出版日: 2019年11月19日
発行: Allied Market Research
ページ情報: 英文 189 Pages
納期: 2-3営業日
|
世界の主要抗がん剤10種の売上は、2018年に636億1,900万米ドルとなりました。同市場は、2019年から2026年の間に9.8%のCAGRで成長する見通しで、2026年には1,299億4,800万米ドルに達すると予測されていますす。
当レポートは世界の主要抗がん剤10種市場について調査しており、市場機会、成長および阻害要因、市場機会、成長および阻害要因、地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。
List of Tables
Table 01. Global Sales of Top 50 Anticancer Drugs, 2018 ($Million)
Table 02. Russia Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 03. Netherlands Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 04. Switzerland Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 05. Sweden Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 06. Belgium Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 07. Austria Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 08. Norway Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 09. Denmark Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 10. Poland Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 11. Finland Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 12. Portugal Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 13. Greece Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 14. Ireland Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 15. Czech Republic Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 16. Hungary Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 17. Romania Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 18. Ukraine Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 19. Taiwan Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 20. Indonesia Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 21. New Zealand Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 22. Singapore Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 23. Malaysia Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 24. Vietnam Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 25. Myanmar Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 26. Sri Lanka Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 27. Macau Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 28. Nepal Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 29. Turkey Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 30. Venezuela Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 31. Colombia Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 32. Argentina Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 33. Iran Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 34. Israel Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 35. Chile Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 36. Algeria Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 37. Uae Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 38. Puerto Rico Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 39. Morocco Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 40. Costa Rica Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 41. Lebanon Top 10 Cancer Drugs Sales, 2018 ($Million)
Table 42. Abbvie: Company Snapshot
Table 43. Abbvie: Operating Segments
Table 44. Abbott: Product Portfolio
Table 45. Astellas: Company Snapshot
Table 46. Astellas: Products And Services
Table 47. Astellas: Product Portfolio
Table 48. Astrazeneca: Company Snapshot
Table 49. Astrazeneca: Operating Segments
Table 50. Astrazeneca: Product Portfolio
Table 51. Bristol-Myers Squibb: Company Snapshot
Table 52. Bristol-Myers Squibb: Product Portfolio
Table 53. Celgene: Company Snapshot
Table 54. Celgene: Operating Segments
Table 55. Celgene : Product Type Portfolio
Table 56. Roche: Company Snapshot
Table 57. Roche: Operating Segments
Table 58. Roche: Product Type Portfolio
Table 59. J&J: Company Snapshot
Table 60. J&J: Operating Segments
Table 61. J&J: Product Type Portfolio
Table 62. Merck: Company Snapshot
Table 63. Merck: Operating Segments
Table 64. Merck: Product Portfolio
Table 65. Novartis: Company Snapshot
Table 66. Novartis: Operating Segments
Table 67. Novartis: Product Portfolio
Table 68. Pfizer: Company Snapshot
Table 69. Pfizer: Operating Segments
Table 70. Pfizer: Product Portfolio
List of Figures
Figure 01. Top Investment Pockets, 2018
Figure 02. Top Player Positioning, 2018
Figure 03. Moderate Barganing Power of Buyers
Figure 04. High Barganing Power of Suppliers
Figure 05. Moderate Threat of Substitution
Figure 06. Moderate Threat of New Entrants
Figure 07. High Competitive Rivalry
Figure 08. World Population Aged 65 And Over (%)
Figure 09. Impact Analysis
Figure 10. European Geriatric Population (Above 65 Years), 2017
Figure 11. Russia Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 12. Netherlands Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 13. Switzerland Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 14. Sweden Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 15. Belgium Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 16. Austria Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 17. Norway Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 18. Denmark Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 19. Poland Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 20. Finland Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 21. Portugal Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 22. Greece Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 23. Ireland Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 24. Czech Republic Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 25. Hungary Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 26. Romania Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 27. Ukraine Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 28. Taiwan Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 29. Indonesia Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 30. New Zealand Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 31. Singapore Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 32. Malaysia Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 33. Vietnam Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 34. Myanmar Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 35. Sri Lanka Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 36. Macau Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 37. Nepal Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 38. Turkey Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 39. Venezuela Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 40. Colombia Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 41. Argentina Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 42. Iran Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 43. Israel Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 44. Chile Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 45. Algeria Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 46. Uae Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 47. Puerto Rico Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 48. Morocco Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 49. Costa Rica Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 50. Lebanon Top 10 Cancer Drugs Market, 2018-2026 ($Million)
Figure 51. Abbvie: Net Sales, 2015-2017 ($Million)
Figure 52. Abbvie: Revenue Share By Segment, 2017 (%)
Figure 53. Abbvie: Revenue Share By Region, 2017 (%)
Figure 54. Astellas: Sales, 2015-2017 ($Million)
Figure 55. Astellas: Sales Share By Products And Services, 2017 (%)
Figure 56. Astellas: Revenue Share By Region, 2017 (%)
Figure 57. Astrazeneca: Revenue, 2015-2017 ($Million)
Figure 58. Astrazeneca: Revenue Share By Region, 2017 (%)
Figure 59. Revenue, 2015-2017 ($Million)
Figure 60. Bristol-Myers Squibb: Revenue Share By Region, 2017 (%)
Figure 61. Celgene: Revenue, 2015-2017 ($Million)
Figure 62. Celgene: Revenue Share By Segment, 2017 (%)
Figure 63. Celgene: Revenue Share By Region, 2017 (%)
Figure 64. Roche: Net Sales, 2015-2017 ($Million)
Figure 65. Roche: Revenue Share By Segment, 2017 (%)
Figure 66. Roche: Revenue Share By Region, 2017 (%)
Figure 67. J&J: Revenue, 2015-2017 ($Million)
Figure 68. J&J: Revenue Share By Segment, 2017 (%)
Figure 69. J&J: Revenue Share By Region, 2017 (%)
Figure 70. Merck: Net Sales, 2015-2017 ($Million)
Figure 71. Merck: Net Sales By Segment, 2017 (%)
Figure 72. Merck: Net Sales By Region, 2017 (%)
Figure 73. Net Sales, 2015-2017 ($Million)
Figure 74. Novartis: Revenue Share By Segment, 2017 (%)
Figure 75. Novartis: Revenue Share By Region, 2017 (%)
Figure 76. Pfizer: Revenue, 2015-2017 ($Million)
Figure 77. Pfizer: Revenue Share By Segment, 2017 (%)
Figure 78. Pfizer: Revenue Share By Region, 2017 (%)
The global top 10 cancer drugs sales was valued at $63,619 million in 2018 and is expected to reach $129,948 million by 2026, registering a CAGR of 9.8% from 2019 to 2026.
Cancer is medical condition in which abnormal cells grow with the potential to invade or spread to other parts of the body. Different forms of the drugs used for the treatment of cancer majorly include, chemotherapy, targeted therapy, immunotherapy, and others.
Increase in prevalence of various forms of cancer, increase in popularity of advance therapies such as biological & targeted drug therapies, and rise in geriatric population worldwide are the key factors that drive the growth of the global cancer drugs market. Furthermore, rise in cancer awareness, increase in R&D activities, and availability of cancer drugs are expected to boost the market growth.
However, high cost involved in new drug development coupled with threat of failure and adverse effects associated with cancer drugs therapies is expected to restrain the growth of the market. Conversely, high potential of emerging economies and increase in number of pipeline products are expected to provide new opportunities for market players in future.
The global top 10 cancer drugs market is segmented on the basis of region into Europe (Russia, Netherlands, Switzerland, Sweden, Belgium, Austria, Norway, Denmark, Poland, Finland, Portugal, Greece, Ireland, Czech Republic, Hungary, Romania, Ukraine), Asia-Pacific (Taiwan, Indonesia, New Zealand, Singapore, Malaysia, Vietnam, Myanmar, Sri Lanka, Macau, Nepal), and LAMEA (Turkey, Venezuela, Colombia, Argentina, Iran, Israel, Chile, Algeria, UAE, Puerto Rico, Morocco, Costa Rica, Lebanon).
By Region
List of key players profiled in the report: